Navigation Links
Par Pharmaceutical Reports Second Quarter 2008 Results
Date:8/7/2008

ED CONSOLIDATED BALANCE SHEETS

(In Thousands, Except Share Data)

(Unaudited)

June 28, December 31,

2008 2007

ASSETS

Current assets:

Cash and cash equivalents $177,656 $200,132

Available for sale debt and marketable

equity securities 115,306 85,375

Accounts receivable, net 61,284 64,182

Inventories 51,774 84,887

Prepaid expenses and other current assets 15,684 14,294

Deferred income tax assets 54,868 56,921

Income taxes receivable 21,715 17,516

Total current assets 498,287 523,307

Property, plant and equipment, at cost less

accumulated depreciation and amortization 84,771 82,650

Available for sale debt and marketable

equity securities 5,156 6,690

Investment in joint venture - 6,314

Other investments 2,500 2,500

Intangible assets, net 55,350 36,059

Goodwill 63,729 63,729

Deferred financing costs and other assets 2,085 2,544

Non-current deferred income tax assets, net 59,252 57,730

Total assets $771,130 $781,523

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Current portion of long-term debt $200,000 $200,000

Accounts payable
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Memory Pharmaceuticals to Announce Second Quarter 2008 Results on Wednesday, August 13, 2008
3. Watson Pharmaceuticals Reports Second Quarter 2008 Results
4. XTELL Launches its Commercial Biorepository Services for Research and Pharmaceutical Companies
5. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
6. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
7. Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
8. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
10. Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
11. Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Synthetic Biologics, ... novel pathogen-specific therapies for serious infections and diseases, announced ... issued a Notice of Allowance for a composition of ... C. difficile program, SYN-004. This is Synthetic ... in the U.S. and adds to the Company,s extensive ...
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/22/2014)... and HONG KONG , Oct. 22, ... therapeutics enterprise, announced today that rare disease expert ... vice president, research. Dr. McKew brings more than two ... positions at the National Institutes of Health, Wyeth Research ... Wyeth). Dr. McKew will lead aTyr,s efforts to expand and ...
(Date:10/20/2014)... Oct. 20, 2014 Mapp Biopharmaceutical,s valiant ... antibody therapeutic to fight the Ebola outbreak will ... time-consuming the production of pharmaceuticals can be, according ... said that while some may be taken aback ... those with industry knowledge are well aware of ...
Breaking Biology Technology:Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Web addicts, take heart: A public-private effort is moving ... , AOL-SkyCable has been chosen to enter negotiations ... for the general public. The "Wireless Wisconsin" service would ... Madison and the Dane County Regional Airport. The project ...
... Information-technology businesses are taking apart their processes ... 2005 CEO-CIO Symposium on Wednesday just around the ... offered their opinions on how the state and its ... year progresses. , Restructuring and rebuilding ,According to ...
... Johnson Controls Inc. has completed ... a French company, Valeo. Valeo is based in ... million) for the business, headquartered in Pontoise, France, ... engines. Johnson Controls bought the division from another ...
Cached Biology Technology:Madison wi-fi plans move ahead 2Restructuring is a watchword for IT in 2005 2Restructuring is a watchword for IT in 2005 3
(Date:10/22/2014)... 20, 2014 The Nano-Bio Manufacturing Consortium (NBMC), ... Research Laboratory (AFRL), has chosen a project proposed by ... University of Arizona College of Medicine – ... project,s goal is to assess different sweat collection methods ... of sweat under a variety of human-body conditions, the ...
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... To date, antidotes ... doctors are often limited to supportive therapy such as induced ... of drugs involved. So what can be done if a ... professor Jean-Christophe Leroux from the Institute of Pharmaceutical Sciences at ... "The task was to develop an agent that could eliminate ...
Breaking Biology News(10 mins):Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 2Nano-Bio Manufacturing Consortium Selects Project Proposed by Arizona Center for Integrative Medicine to Optimize Human Performance Monitoring Techniques 3Whole-exome sequencing shows potential as diagnostic tool 2Emergency aid for overdoses 2Emergency aid for overdoses 3
... SAN FRANCISCO An increasing number of obese adolescents, ... case study presented Sunday, Oct. 3, at the American ... San Francisco, highlights the possible link between gastric bypass ... neural tube defects, which can lead to varying degrees ...
... of private health insurance and its consequent lack of ... with uterine cancer and may partly explain the mortality ... data presented at the Third AACR Conference on The ... twice as likely to die within four years compared ...
... breast cancer that lacked estrogen and progesterone receptors and did ... those with other types of invasive breast cancer, according to ... Science of Cancer Health Disparities, held Sept. 30 Oct. ... in Puerto Rico, following U.S. trends, it is important to ...
Cached Biology News:Loss of nutrients following gastric bypass surgery in adolescent girls 2Lack of private health insurance impacted cancer survival 2Decreased survival for Puerto Rican women with 'triple-negative' breast cancer subtype 2
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
Parathyroid Hormone Receptor 2 [PTHR2]...
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Biology Products: